TABLE 2.
Compounds targeting galectins in clinical trials.
| Compound | Clinical Trial/NCT | |
|---|---|---|
| Gal-3 | TD139 | Idiopathic Pulmonary Fibrosis (NCT03832946) |
| COVID-19 (NCT04473053) | ||
| GCS-100 | Chronic Kidney Disease (NCT01843790) | |
| Chronic Lymphocytic Leukemia (NCT00514696) | ||
| Multiple Myeloma (NCT00609817) | ||
| Belapectin | Varying Degrees of Hepatic Impairment (NCT04332432) | |
| Gal-1/3 | GM-CT-01 | Melanoma (NCT01723813) |
| Metastatic Colorectal Cancer (NCT00110721) | ||
| Solid Tumors (NCT00054977) | ||
| Gal-1 | OTX008 | Advanced Solid Tumors (NCT01724320) |